Orchid completes cephalosporins project in ChinaIllustrative image – not actual.

Orchid Chemicals & Pharmaceuticals has commenced operations at its newly set up facility in China. The company has started manufacture of sterile cephalosporin bulk actives and their formulations while production of sterile lyophilisation block is expected to begin by end October 2003.

 

The project is being established in joint venture with North China Pharmaceutical Corporation, entailing an investment of $25 million (approx Rs.115 crore).

 

It may be noted that Orchid already has two overseas joint ventures – in USA with BEXEL for drug discovery in metabolic diseases and with IBPP in Europe for peptic drugs and niche products.

 

Orchid’s investment in the three overseas ventures is pegged at around $15 million (approx Rs.70 crore) of which, a capital expenditure of $9 million (approx Rs.42 crore) has been incurred. The remaining $6 million (approx 28 crore) is to be invested over the next 2-3 years.

← All latest storiesBack to top →